The Effect of Rosuvastatin on Low-Density Lipoprotein Subfractions in Patients With Impaired Fasting Glucose J Cardiovasc Pharmacol Ther published online 18 September 2014

Posted in Uncategorized

Preamble of the study

  • Statins are the cornerstone of hypercholesterolemia treatment
  • Among statins, rosuvastatin is considered the most potent in beneficially modifying the serum lipid profile and altering LDL subfraction distribution
  • On the other hand, statin treatment has been associated with the development of new-onset diabetes mellitus
  • To date, it is unclear whether statin intervention in patients with dyslipidemia having impaired fasting glucose (IFG) better modifies the serum lipid profile as well as the quality synthesis of LDL particles

 

Rizos CV et al. aimed to examine the potentially differential effect of rosuvastatin on the quantity and quality of LDL-C in patients with dyslipidemia having IFG compared with normoglycemic patients with dyslipidemia

Salient Features of the Study

  • This was a prospective observational study including patients with dyslipidemia and IFG (IFG group, n=49) matched with normoglycemic patients with dyslipidemia (control group, n=64)
  • Study participants, following dietary intervention, were prescribed rosuvastatin 10 or 20 mg/d to achieve LDL-C goals
  • Baseline as well as 24 weeks post-treatment changes in the serum lipid profile were evaluated
  • Similar effects were observed in lipid profile in both treatment groups
  • Patients with IFG experienced a greater decrease in the cholesterol concentration of small dense LDL particles (-65.7%, p<0.001 vs baseline) compared to controls (-38.5%, p<0.001 vs baseline; p=0.018 vs patients with IFG) – pls see Table below
  • A greater increase in the mean LDL particle size (+1.5%, p<0.001 vs baseline) was noted in the IFG group compared to the control group at 24 weeks (+0.4%, p=0.028 vs baseline; p=0.008 vs IFG group)

Conclusion

The authors concluded that targeting dyslipidemia with rosuvastatin was associated with more favorable changes in the LDL sub-fraction profile in patients with IFG compared to normoglycemic patients

The article can be accessed at the below mentioned link:

http://cpt.sagepub.com/content/early/2014/09/18/1074248414549419.1.full.pdf+html

Published by drvivekbaliga

Dr Vivek Baliga is a medical practitioner. His area of expertise includes diabetes, heart disease, and general medicine. Over the last 15 years, he has been practising the field, and works at Baliga Diagnostics in Bangalore, of which he is the director. Dr Vivek Baliga also is a keen blogger, with his own health blog at https://drvivekbaliga.com and https://heartsense.in. He is a visiting senior consultant at various hospitals, and dedicates his spare time to his family and teaching online.

Leave a comment